Transenterix Inc. isn't giving up on the U.S. Surgical robotics market. During a Friday morning conference call to discuss the company's second quarter earnings – which included a $80.1 million net loss – executives said their focus is now on getting FDA approval for the Alf-x robot. But the company still plans to eventually seek approval for the Surgibot robot, which the FDA rejected earlier this year, noting that the device did not meet the criteria for substantial equivalence based on the company's submitted data. Read More
